Mast cell inflammatory mediator pathways

Mast cell inflammatory mediator pathways represent the complex intracellular signaling networks and effector processes that lead to the release of bioactive molecules from mast cells. These pathways are most commonly initiated by the cross-linking of the high-affinity IgE receptor (FcεRI) by allergens, but can also be triggered by non-IgE stimuli such as the MRGPRX2 receptor, complement components, and neuropeptides (Theoharides et al., 2012). Upon activation, mast cells undergo a rapid process of degranulation, releasing preformed mediators like histamine, heparin, and neutral proteases such as tryptase into the extracellular environment (Stone et al., 2010). This is followed by the de novo synthesis of lipid-derived mediators, including leukotriene C4 and prostaglandin D2, and the subsequent secretion of a wide array of cytokines and chemokines (Valent et al., 2012). These pathways are central to the pathogenesis of Type I hypersensitivity reactions, including allergic rhinitis, asthma, and life-threatening anaphylaxis, as well as chronic conditions like mast cell activation syndrome (MCAS) and mastocytosis. Therapeutic interventions targeting these pathways include mast cell stabilizers like cromolyn sodium, which prevent degranulation, and monoclonal antibodies like omalizumab that sequester IgE. Additionally, various antagonists are used to block the receptors of the released mediators, such as H1-antihistamines and leukotriene receptor antagonists. Kinase inhibitors like imatinib and midostaurin are also employed to target the KIT receptor, which is a critical regulator of mast cell survival and activation. Understanding these pathways is essential for developing precision therapies for mast cell-driven inflammatory diseases.

Other names

Mast cell activation pathwaysMast cell degranulationFcεRI signaling pathwayMast cell mediator release

Pharmacological agents modulate these pathways by stabilizing the mast cell membrane to prevent the release of granules, inhibiting the binding of IgE to its high-affinity receptor, or antagonizing the specific receptors (e.g., H1, CysLT1) of the mediators once they are released.